A premotor disease signature for ALS.

The premodiALS consortium is an initiative funded within the 2021 EU Joint Programme - Neurodegenerative Disease Research (JPND) call for proposals: "Linking pre-diagnosis disturbances of physiological systems to Neurodegenerative Diseases"

Amyotrophic lateral sclerosis (ALS) is the most frequent motoneuron disease with a devastating  prognosis. Patients with ALS progressively lose their ability to voluntarily move their muscles. This includes muscles in the extremities, but also muscles responsible for respiration, swallowing and speech. Even today, it takes on average 12 months from the onset of motor symptoms to establish the diagnosis of ALS and approximately half of the patients are initially misdiagnosed. Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies.

Researchers from 10 countries join forces for the premodiALS project.

Interested in participation?

Download here our participant information for more information on how to contribute to premodiALS: